Kura Oncology grants CFO options on 450K shares

Kura Oncology’s CFO received a 450,000-share stock option grant at a $12.52 exercise price under a Rule 10b5-1 plan.

Available on EDGAR 09/10/2026 - 04:30 PM EDT Accepted by SEC EDGAR 09/10/2026 - 04:30 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Kura Oncology, Inc. (KURA) reported that Chief Financial Officer Jennifer Fulk received a grant of stock options covering 450,000 shares of common stock on September 8, 2026. The options have an exercise price of $12.52 per share and expire on September 7, 2036, and no shares were bought or sold.

The grant was reported as made pursuant to a Rule 10b5-1 trading plan. According to the vesting terms, one-fourth of the options vest on the one-year anniversary of the vesting commencement date, with the remainder vesting in monthly installments thereafter.

Insider Trade Summary 10b5-1

Grant/Award: 450,000 shares

Grant/Award 1 txn

Insider Fulk Jennifer

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Option to purchase common stock F1	450,000	$0.00	$0.00

Holdings After Transaction: Option to purchase common stock — 450,000 contracts (Direct)

Holdings Before and After: Option to purchase common stock, 0 to 450,000 contracts (Direct)

Footnotes (1)

1. F1. 1/4th of the shares vest on the one year anniversary of the vesting commencement date, and 1/48th of the shares vest in 36 monthly installments thereafter.

Key Figures

Stock options granted: 450,000 options Exercise price: $12.52 per share Expiration date: September 7, 2036 +1 more

4 metrics

Stock options granted 450,000 options Grant to CFO Jennifer Fulk on September 8, 2026

Exercise price $12.52 per share Exercise price of CFO’s 450,000-share option grant

Expiration date September 7, 2036 Expiration of the granted stock options

Shares underlying options 450,000 shares Common shares underlying the reported option grant

Key Terms

Rule 10b5-1 trading plan, stock options, vesting commencement date, exercise price

4 terms

Rule 10b5-1 trading plan regulatory

"The grant was reported as made pursuant to a Rule 10b5-1 trading plan."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

stock options financial

"Chief Financial Officer Jennifer Fulk received a grant of stock options covering 450,000 shares."

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

vesting commencement date financial

"1/4th of the shares vest on the one year anniversary of the vesting commencement date."

The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.

exercise price financial

"The options have an exercise price of $12.52 per share."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity award did KURA grant to its CFO Jennifer Fulk?

Kura Oncology granted Jennifer Fulk a stock option covering 450,000 shares of common stock, with an exercise price of $12.52 per share and an expiration date of September 7, 2036.

Was the KURA Form 4 transaction under a Rule 10b5-1 plan?

Yes. The filing indicates the reported stock option grant to Kura Oncology’s CFO was made pursuant to a Rule 10b5-1 trading plan.

How do the KURA CFO’s new stock options vest?

For the 450,000-share option grant, 1/4 of the shares vest on the one-year anniversary of the vesting commencement date, and 1/48 of the shares vest in each of the following 36 monthly installments.

Did the KURA CFO buy or sell any common shares in this Form 4?

No. The Form 4 reports only a grant of stock options to purchase 450,000 shares; it does not report any open-market purchases or sales of Kura Oncology common stock.

What is the total number of options the KURA CFO holds after this grant?

After the reported grant, the CFO holds 450,000 stock options directly, as shown in the post-transaction derivative holdings in the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fulk Jennifer

(Last) (First) (Middle)

C/O KURA ONCOLOGY, INC.

4930 DIRECTORS PLACE, SUITE 500

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kura Oncology, Inc. [ KURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to purchase common stock	$12.52	09/08/2026		A		450,000		(1)	09/07/2036	Common Stock	450,000	$0.00	450,000	D

Explanation of Responses:

1. 1/4th of the shares vest on the one year anniversary of the vesting commencement date, and 1/48th of the shares vest in 36 monthly installments thereafter.

	Teresa Bair, Attorney-in-fact for Jennifer Fulk	09/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)